Retatrutide vs. Tirzepatide: Scientific Comparison for Research

EXOMA Scientific Team · Publicado el 8 de mayo de 2026 · Actualizado el 17 de agosto de 2026

Comparative analysis between Retatrutide (triple GLP-1/GIP/GCG agonist) and Tirzepatide (dual GLP-1/GIP) in preclinical data and phase II trials.

Executive summary

Retatrutide and Tirzepatide are two peptide analogs designed for advanced metabolic research. Both share the same experimental objective —modulation of the incretin axis for weight-reduction studies— but their pharmacological profile differs substantially.

This information is intended exclusively for scientific research. It does not replace specialized medical supervision.

Mechanism of action

Retatrutide

Retatrutide simultaneously activates the receptors GLP-1, GIP y glucagon. The addition of the glucagon component increases basal energy expenditure in preclinical models through hepatic thermogenesis, which differentiates it from any other incretin analog investigated to date.

Tirzepatide

Tirzepatide is a dual GLP-1/GIP agonist. Its effect on satiety and glycemic control is well characterized in peer-reviewed literature, with the SURMOUNT and SURPASS trials establishing the reference pharmacodynamic profile.

Comparative data in the literature

The phase II trials published in The New England Journal of Medicine (Jastreboff et al., 2023; Rosenstock et al., 2023) show similar weight-reduction trajectories in the first 24 weeks, with divergence in favor of Retatrutide after week 36 at high doses (8-12 mg weekly).

Analytical purity

For reproducible research it is recommended to require:

• documented in COA per lot
• Analysis of molecular mass by spectrometry (MALDI-TOF or ESI-MS)
• Verification of endotoxins per LAL test
• Chain of custody verifiable batch

Both peptides in the Exoma catalog are shipped with a per-batch COA issued by the partner laboratory Chromasys.

Reconstitution and handling

Both lyophilized compounds are reconstituted with bacteriostatic water (0.9% benzyl alcohol) for research. The concentration recommended in preclinical literature is 5-10 mg/mL to facilitate precise volumetric dosing.

For detailed reconstitution protocols, consult our technical guide.

Stability

Methodological conclusion

The choice between the two compounds depends on the experimental objective:

• Retatrutide: research on thermogenesis and energy expenditure (presence of the glucagon component).
• Tirzepatide: research on glycemic control and satiety with a pharmacological profile more characterized in the clinical literature.

Both require strict aseptic handling and analytical quantification before beginning any experimental protocol.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID 37366315. (humano, ensayo clínico fase 2)
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647. (humano, ensayo clínico fase 3 — SURPASS-2)
3. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340. (in vitro/animal and human phase 1)

Products available at EXOMA

• Retatrutide
• Tirzepatide